Sequencing Considerations and CNS Management

The discussion addresses whether preserving sequencing flexibility should influence first-line treatment selection for patients with borderline fitness and small asymptomatic brain metastases. Dr. Rodriguez argues against allowing sequencing concerns to compromise optimal first-line therapy selection.

Both FLAURA2 and MARIPOSA demonstrate superior overall survival and intracranial efficacy compared to monotherapy. FLAURA2 monitoring focused on patients with baseline brain metastases, demonstrating 30-month median duration of response through pemetrexed's CNS activity.

The panelists emphasize giving optimal first-line treatment rather than compromising based on hypothetical future scenarios. Multiple second-line options exist, and sequencing concerns should not deter clinicians from providing evidence-based standard care.

Dr. Olazagasti highlights concerns about reserving aggressive therapy for progression, noting that patient performance status, resistance patterns, and disease biology evolve unpredictably. Patients with poor-risk features may not remain fit for subsequent intensive therapies, and disease transformation or leptomeningeal spread represents particularly concerning progression patterns.

The survival advantages of 10+ months observed with combination regimens partially reflect superior management of CNS disease and potential disease transformation. Early aggressive intervention may prevent these life-threatening complications more effectively than sequential treatment approaches.

Historical experience demonstrates that many patients experience rapid clinical deterioration at progression, becoming ineligible for subsequent intensive therapies. The assumption that patients will remain candidates for multiple treatment lines may prove overly optimistic for high-risk populations requiring early intervention strategies.